Opinion

Video

Dose Modifications and Tolerability Associated with mCRC Treatment Regimens

Author(s):

Aparna R. Parikh, MD,Marwan G. Fakih, MD

Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.

Related Videos
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Andrew Kuykendall, MD
Prithviraj Bose, MD, and Chandler Park, MD, FACP
Peter Forsyth, MD
Richard Kim, MD, Moffitt Cancer Center
Related Content
OncLive's OncFive: The Top 5 Oncology Articles of the Week
December 21st 2024

The OncFive: Top Oncology Articles for the Week of 12/15

Alex F. Herrera, MD, chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, associate medical director, Briskin Center for Clinical Research, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
December 13th 2024

Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD

Mantle Cell Lymphoma | stock.adobe.com
December 17th 2024

Glofitamab Produces Durable Remissions in R/R Mantle Cell Lymphoma

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Nicole Lamanna, MD, associate clinical professor, medicine, Hematologic Malignancies Section, Hematology/Oncology Division, Columbia University Herberg Irving Comprehensive Cancer Center
November 25th 2024

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD

Epcoritamab Monotherapy in R/R CLL | Image Credit: © LASZLO – stock.adobe.com
December 8th 2024

Epcoritamab Monotherapy Induces Complete Responses in R/R CLL

Cathy Eng, MD, FACP, FASCO
December 6th 2024

NGS and ctDNA Testing Guide Treatment Selection and Sequencing in mCRC